BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12952019)

  • 1. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A; Crombet T; González G
    Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Fay JR; Steele VE; Lubet RA; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):657-66. PubMed ID: 8824370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J; Baselga J
    J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.
    Kataoka H
    J Dermatol Sci; 2009 Dec; 56(3):148-53. PubMed ID: 19896805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epidermal growth factor receptor in head and neck cancer.
    Ford AC; Grandis JR
    Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
    Ang KK; Andratschke NH; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
    Astsaturov I; Cohen RB; Harari P
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor family receptors and inhibitors: radiation response modulators.
    Sartor CI
    Semin Radiat Oncol; 2003 Jan; 13(1):22-30. PubMed ID: 12520461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of EGFR in malignant gliomas.
    Ye F; Gao Q; Cai MJ
    Expert Opin Ther Targets; 2010 Mar; 14(3):303-16. PubMed ID: 20148717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.